Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

被引：216

作者：

Sakoulas, G

Alder, J

Thauvin-Eliopouios, C

Moellering, RC

Eliopoulos, GM

机构：

[1] New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA

[2] Westchester Cty Med Ctr, Valhalla, NY 10595 USA

[3] Cubist Pharmaceut, Lexington, MA USA

[4] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA

[5] Harvard Univ, Sch Med, Boston, MA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 04期

关键词：

D O I：

10.1128/AAC.50.4.1581-1585.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We studied vancomycin and daptomycin susceptibility in methicillin-resistant Staphylococcus aureus from patients exposed to vancomycin, glycopeptide-intermediate S. aureus, and S. aureus passaged in vancomycin-containing medium. A correlation between vancomycin and daptomycin heteroresistance was noted in some strains, suggesting that exposure of S. aureus to vancomycin may affect susceptibility to daptomycin.

引用

收藏

页码：1581 / 1585

页数：5

相关论文

共 19 条

[1] Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].

Akins, RL ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459

[2] DAPTOMYCIN DISRUPTS MEMBRANE-POTENTIAL IN GROWING STAPHYLOCOCCUS-AUREUS [J].

ALBORN, WE ;

ALLEN, NE ;

PRESTON, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (11) :2282-2287

[3]

[Anonymous], 2000, M7A5 NAT COMM CLIN L, pM7

[4] Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 [J].

Fridkin, SK ;

Hageman, J ;

McDougal, LK ;

Mohammed, J ;

Jarvis, WR ;

Perl, TM ;

Tenover, FC .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :429-439

[5] Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus [J].

Geisel, R ;

Schmitz, FJ ;

Fluit, AC ;

Labischinski, H .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (10) :685-697

[6] Mechanisms of action of newer antibiotics for Gram-positive pathogens [J].

Hancock, REW .

LANCET INFECTIOUS DISEASES, 2005, 5 (04) :209-218

[7]

Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3

[8] Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus [J].

Koehl, JL ;

Muthaiyan, A ;

Jayaswal, RK ;

Ehlert, K ;

Labischinski, H ;

Wilkinson, BJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3749-3757

[9]

Maslow Joel N., 1993, P563

[10] Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA [J].

Meka, VG ;

Pillai, SK ;

Sakoulas, G ;

Wennersten, C ;

Venkataraman, L ;

DeGirolami, PC ;

Eliopoulos, GM ;

Moellering, RC ;

Gold, HS .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (02) :311-317